PhosChol
  • Home
    • Advanced Lipid Science
    • Disclaimer
  • About
    • Why PhosChol
  • Areas Of Use
    • Liver
    • Liver Report
    • Heart
    • Lipoprotein Metabolism
    • Diabetes
    • Brain
    • ASD
    • Gut Health
    • Mitochondria
    • Sport and Endurance
  • Doctors Direct
    • Prescribing information
    • Efficacy
  • Product Page
  • FAQ's
  • Contact

Picture
PhosChol:
A Membrane Therapeutic for Liver Disturbances

According to the intensity of exposure to noxae, malnutrition or viruses, liver damage may manifest itself as:
  • acute and chronic hepatitus
  • fatty liver
  • liver cirrhosis
  • others
PPC is a superior protectant against liver damage.
Irrespective of the origin, damage to liver cell membranes and to their organelles is generally present in hepatopathies. Metabolic functions of the liver cell and the activity of enzymes bound to membranes are inhibited, thus causing the clinical picture of liver disorders.


PhosChol: A Membrane Therapeutic for Liver Disturbances

PPC is incorporated into liver cell membranes in toto as shown with the help of double-radioactive labeling. Clinical studies
suggest that PPC:
  • Restructures Damaged Membranes 1—3
  • Normalizes Cellular Permeability 4
  • Improves Cell Metabolism 5—7
  • Reactivates Membrane-Bound Enzymes 8—9
  • Stimulates Hepatocyte Regeneration 10—11

For Use In Acute and Chronic Disorders of the Liver

Every year doctors around the world prescribe polyenylphosphatidylcholine (PPC) to millions of patients with liver disorders. The positive experience doctors and patients have with PPC, the main ingredient in PhosChol, is due to its unique mode of action.
  • PPC corresponds in its chemical structure to endogenous phospholipids. Due to its high content of bound polyunsaturated fatty acids, however, they are much superior to these.
  • PPC is incorporated into all cell membrane systems of the cells and organelles, and thus constitutes an integrative component of the membrane.
  • PPC plays a decisive role in membrane dependent metabolic processes as well as in cell regeneration.
  • Phospholipid-dependent, membrane-located enzyme activity increases in the presence of PPC.
  • The polyunsaturated fatty acids released from a part of the molecules constitute prostaglandin precursors.
  • PPC co-regulates immunological processes.
  • PPC stabilizes the membranes and counteracts lipid peroxidation due to free radicals.

Loss of phospholipids is seen irrespective of the etiology in liver disorders in which there is damage to the hepatocyte membranes and organelles. Exogenous substitution of phospholipids in the form of PPC leads to the incorporation of PPC into the membranous structures of the liver cell and thus to membrane regeneration. The proof of the unique mode of action and thus the therapeutic relevance of PPC was primarily demonstrated by a large number of different pharmacological studies carried out all over the world and now is continually completed on the basis of new scientific methods.

Clinical Studies Confirm:  In numerous international clinical studies with more than 10,000 patients, well-known clinicians checked the therapeutic possibilities of PPC in the treatment of liver disorders of different etiology and confirmed the knowledge gained during pharmacological examinations.

References & Areas of UseReferences:
  1. Zierenberg, O. and Grundy, S.M., J. Lipid. Res., 23:1136 (1982).
  2. Dargel R. et al., Z. Gastroenteral. 29 (Suppl. 2):18 (1991).
  3. Lekim, D. and Betzing, H., Arzneimit Forsch, 2: 1772 (1976).
  4. Indovina, J. et al., Epatologica, 27:261 (1981).
  5. Navder K. P. and Lieber C. S., Biochem. Biophys. Res. Commun. 291:1109 (2002).
  6. Müting, D. et al., Verh. Dtsch. Ges. innere Med., 78:1389 (1972).
  7. Kuntz, H. D. it al., Med. Welt., 29:452 (1978).
  8. Chanussot, F. and Benaoel, L., Life Sciences 73:381 (2003).
  9. Saratikov A.S. and Vengerovskii A.I., Biull. Eksp. Biol. Med. 127:392 (1999).
  10. Alliet, J. et al., L’Quest Medical, 29:85 (1976).
  11. Holecek, M. et al., in: Liver and Drugs 1994 edt. by J. Holoman and J. Glasa. Progress in Hepato-Pharmacol. 1:202 (1995).

Areas of Use: As adjuvant in acute and chronic hepatitis; cirrhosis; intoxications; fatty degeneration of the liver of any origin; functional cholestasis; prophylaxis of gallstone formation; radiation syndrome; pre-and postoperative care, especially in liver/gallbladder surgery.
Dosage and Administration:
​
Unless otherwise prescribed by the physician, 2-3 grams (2-3 capsules or 1 tsp. liquid concentrate) once daily. To be administered during meals, with a little liquid if required. For optimal results, we suggest splitting the dose AM - PM.
Powered by Create your own unique website with customizable templates.